Home›Companies›Biotech & Pharma›Evia Bio

Evia Bio, Inc.

Cell preservation products and services for cell therapy companies.

Updated Nov 9, 2026·Latest SEC filing Sep 28, 2026·Suggest an edit

About Evia Bio

Evia Bio is a private company based in Minneapolis, Minnesota. It has reported $5,453,532 raised in one offering on Form D since September 2026. Its chief executive is Jeffrey Allen.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 14, 2026Sep 28, 2026$5,453,532fully sold19$287KEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Evia Bio's Form D filed Sep 28, 2026.

Allison Hubel
Allison Hubel
Founder and Scientific Advisor, director
SF
Scott Fisher
Director
TW

Sources

  1. SECEvia Bio, Inc. filing history
  2. CompanyEvia Bio team
  3. CompanySeries A announcement